JVS-100
Phase 2Biologic
JVS-100 is one of 54 biologic programs targeting Heart Failure. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Brethine
SanofiPreclinical
Amidate
PfizerPreclinical
Medrol
PfizerPreclinical
LCZ696
NovartisPreclinical
Zemplar
AbbViePreclinical
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Xifaxan
SSalix
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
JVS-100
JJuventas Therapeutics, Inc.
Phase 2
Coumadin
AAbbott
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JVS-100. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- JJuventas Therapeutics, Inc.